

Condensed Consolidated Financial Statements (Expressed in U.S. Dollars)

As at and for the six-months ended November 30, 2018

	Page
CONSOLIDATED FINANCIAL STATEMENTS	
Condensed Consolidated Interim Statements of Financial Position	4
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss	5
Condensed Consolidated Interim Statements of Cash Flows	6
Condensed Consolidated Interim Statements of Changes in Equity	7
Notes to the Condensed Consolidated Interim Financial Statements	8 - 29

No Auditor Review of the Condensed Consolidated Interim Financial Statements

The accompanying unaudited condensed consolidated interim financial statements of Certive Solutions Inc. (the "Company"), as at and for the six-month period ended November 30, 2018 have been prepared by management and have not been the subject of a review by the Company's external independent auditors.

not occir une suoject of a review by une con	ipanij o ememu in	acpendone dudicors.	
Certive Solutions Inc.			
Vancouver, British Columbia January 29, 2019			
Approved on behalf of the Board of Director	ors:		
"Timothy J Hyland" Timothy J Hyland	_Director	"Thomas Marreel" Thomas Marreel	_Director

Condensed consolidated interim statements of financial position as at (*Unaudited - Expressed in U.S. Dollars*)

	Notes	November 30, 2018	May 31, 2018
ASSETS			
Current assets			
Cash		\$ 91,851	\$ 20,141
Marketable securities	4	24,058	7,474
Receivables	5	461,883	345,964
Total current assets		577,792	373,579
Non-Current Assets			
Customer list	6	515,855	515,855
Software development	7	333,794	372,933
Total non-current assets		849,649	888,788
Total assets		\$ 1,427,441	\$ 1,262,367
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			2 2 0
Accounts payable and accrued liabilities	8	\$ 2,860,764	\$ 2,673,18
Deferred revenue Convertible debt	10	128,529	98,00° 2,527,14°
Short term loans	11, 14	3,224,454 458,792	139,320
Note Payable – current portion	9,14	250,000	250,000
Total current liabilities	7,14	6,922,539	5,687,65
Non-current liabilities		0,722,557	3,007,03
Derivative liability	13	427,794	489,170
Long term loans	9,14	250,000	250,000
Total liabilities	,	7,600,333	6,426,820
Shareholders' Equity (Deficit)		7,000,555	0,420,020
Share capital	12	21,376,579	21,030,282
Shares to be issued			98,52
Reserve – Transaction costs		(655,877)	(655,877
Reserve – Share options		1,854,015	1,854,013
Reserve – Share warrants		760,095	760,09
Equity portion of convertible debt		459,636	424,833
Other equity instruments		600,000	840,000
Contributed surplus		766,829	766,829
Deficit		 (31,334,169)	(30,283,161
Total shareholders' deficit		 (6,172,892)	(5,164,459)
Total shareholders' deficit and liabilities		\$ 1,427,441	\$ 1,262,367

Nature of operations and going concern (Note 1) Subsequent events (Note 18)

Certive Solutions Inc.
Condensed consolidated interim statements of loss and comprehensive loss for the periods ended: (*Unaudited - Expressed in U.S. Dollars*)

	Notes	Three months ended November 30, 2018	Three months ended November 30, 2017	Six months ended November 30, 2018	Six months ended November 30, 2017
REVENUE					
Consulting revenue		59,144	56,282	102,048	117,134
Chargemaster revenue		382,403	355,170	579,019	692,470
Dashboard sales		74,224	35,940	114,664	75,348
Total revenue		515,771	447,392	795,731	884,952
OPERATING COSTS					
Commission		24,130	7,320	50,449	17,172
Contractors and consulting fees		88,355	85,461	158,074	176,383
Direct payroll and employee benefits	14	444,694	243,060	650,292	474,355
Travel to client sites		1,162	999	1,162	4,082
Licence fees		-	-	165	150
Total operating costs		558,341	336,840	860,142	672,142
Gross profit EXPENSES		(42,570)	110,552	(64,411)	212,810
Advisory board fees	14	12,000	22,500	12,000	45,000
Amortization	7	19,569	19,568	39,139	45,387
Bank charges and interest	,	129,566	143,304	317,176	250,545
Consulting fees	14	51,572	91,800	99,972	172,300
Corporate finance	14	12,000	7,200	16,000	60,600
Directors' fees	14	12,000	40,000	10,000	122,200
Foreign exchange	1-7	(15,824)	13,581	(57,031)	41,244
General and administrative		41,302	51,475	80,207	97,936
Investor relations		11,002	51,	00,207	7,500
Management fees	14	54,000	141,000	54,000	288,000
Professional fees	14	51,026	146,761	141,193	242,792
Rent		60,864	76,174	126,442	114,549
Salaries and wages	14	26,465	218,279	205,803	419,486
Sales and marketing	1-7	20,403	210,277	203,003	542
Transfer agent and filing fees		8,194	11,227	13,225	17,381
Travel and promotion		2,747	40,920	6,961	77,074
Total expenses		(453,481)	(1,023,789)	(1,065,087)	(2,002,536)
		(496,051)	(913,237)	(1,129,498)	(1,789,726)
Unrealized gain on marketable securities	4	6,120	-	17,114	-
Derivative recovery (expense)	13	52,412	183,468	61,376	(14,616)
Net loss and comprehensive loss for the period	\$	(437,519)	\$ (729,769)	\$ (1,051,008)	\$ (1,804,342)
•					
Basic and diluted loss per common share	\$	(0.01)	\$ (0.01)	\$ (0.01)	\$ (0.02)
Weighted average number of common share outstanding		81,562,623	70 027 420	80 202 127	70 027 420
snare outstanding		01,302,023	79,037,430	80,293,127	79,037,430

Condensed consolidated interim statements of cash flows for the six-month periods ended November 30, (*Unaudited - Expressed in U.S. Dollars*)

		2018		2017
CASH FLOWS FROM OPERATING ACTIVITIES				
Net loss for the period	\$	(1,051,008)	\$	(1,804,342)
Items not affecting cash:	Ψ	(1,031,000)	Ψ	(1,004,542)
Amortization		39,139		45,387
Shares issued for consulting fees		7,772		-3,307
Accretion		154,153		103,991
Amortization of finance costs		155,779		93,968
Foreign derivative		(61,376)		14,616
Foreign exchange		(147,287)		20,557
Unrealized gain marketable securities		(17,114)		20,337
Non-cash working capital item changes:		(17,111)		
Receivables		(115,919)		26,213
Prepaid and other assets		(110,515)		16,597
Accounts payable and accrued liabilities		187,583		662,803
Deferred Revenue		30,522		-
Net cash used in operating activities		(817,756)		(820,210)
CASH FLOWS FROM INVESTING ACTIVITIES				
Acquisition of software development		_		(24,597)
Cash received from Titan		_		100,000
Net cash used in investing activities		-		75,403
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds repayment from Short term loan		(10,534)		72,131
Proceeds from convertible debt		570,000		664,294
Demand loans reserved		330,000		-
Net cash from financing activities		889,466		736,425
Net change in cash during the period		71,710		(8,382)
Cash, beginning of the period		20,141		138,258
Cash, end of the period	\$	91,851	\$	129,876
Cash (paid) received for				
Interest	\$	-	\$	-
Taxes	\$	_	\$	-

Non-cash transactions:

During the period ended November 30, 2018:

- the Company issued 1,300,000 shares valued at \$240,000 which were recorded as other equity instruments.
- the Company issued 3,125,000 shares valued at \$98,525 which were reserved to be issued.
- the Company issued 374,326 shares valued at \$7,772 issued for consulting fees.

•

During the period ended November 30, 2017:

- the Company transferred \$148,140 from short-term debt to convertible notes
- the Company issued 1,666,700 shares valued at \$55,319 as a transaction cost on convertible debt.
- the Company recorded \$99,763 as a transaction cost on convertible debentures that will be settled by the issuance of 3,125,000 shares.

Condensed consolidated interim financial statements of changes in equity (deficit) for the periods ended November 30, 2018 and 2017. (*Unaudited - Expressed in U.S. Dollars*)

Capital Stock

	Number of Shares		Amount	_	Shares to be issued		Reserve Transaction costs		Reserve Share options		Reserve Warrants		Contributed surplus		Other equity instruments		Equity portion of convertible debt		Deficit		Total
Balance, May 31, 2017	79,611,397	\$	21,057,849	\$	-	\$	(612,593)	\$	1,854,015	\$	487,220	\$	766,829	\$	840,000	\$	300,715	\$	(25,119,233)	\$	(425,198)
Shares returned to treasury on discontinuation of Titan Transaction costs on	(2,240,667)		(82,886)		-		-		-		-		-		-		-		-		(82,886)
convertible debt Convertible debt issued	1,666,700		55,319		99,763		(34,173)		-		167,895		-		-		84,931		-		288,804 84,931
Loss for the period Balance, November 30, 2017	79,037,430	\$	21,130,282	¢	99,763	\$	(646,766)	¢	1,854,015	¢	655,115	\$	766,829	¢	840,000	•	385,646	¢	(1,804,342) (26,923,575)	¢	(1,804,342) (1,938,691)
Baiance, November 30, 2017	79,037,430	φ	21,130,262	φ	99,703	φ	(040,700)	φ	1,034,013	φ	033,113	φ	700,829	φ	840,000	φ	363,040	φ	(20,923,373)	φ	(1,938,091)
Balance, May 31, 2018 Convertible Debt Issued Shares issued for prior convertible debt transaction	79,037,430	\$	21,030,282	\$	98,525	\$	(655,877)	\$	1,854,015	\$	760,095 -	\$	766,829	\$	840,000	\$	424,833 34,803	\$	(30,283,161)	\$	(5,164,459) 34,803
cost	3,125,000		98,525		(98,525)		-		-		-		-		-		-		-		-
Shares issued for prior acquisition of Omega Shares issued for consulting Loss for the period	1,300,000 374,326		240,000 7,772				-						-		(240,000)		-		- (1,051,008)		7,772 (1,051,008)
Balance, November 30, 2018	83,836,756	\$	21,376,579	\$	-	\$	(655,877)	\$	1,854,015	\$	760,095	\$	766,829	\$	600,000	\$	459,636	\$	(31,334,169)	\$	(6,172,892)

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

1. NATURE OF OPERATIONS AND GOING CONCERN

Certive Solutions Inc. (the "Company") was incorporated under the Laws of British Columbia and is traded on the Canadian Security Exchange ("CSE") and is quoted on the OTCQB in the United States. The Company provides revenue cycle management services to U.S. hospitals, delivered collaboratively, utilizing proprietary workflow document management and analytics tools tailored to health care business processes. The Company is currently focused on the lost charge recovery segment of revenue cycle management in a revenue sharing relationship that improve hospitals' net operating results. In addition, the Company licenses its dashboard software package to public health agencies across the United State.

The mailing address of the head office of the Company is 1185 West Georgia Street, Suite 1140, Vancouver, BC V6E 4E6.

The condensed consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise indicated, which is the Company's functional currency.

These condensed consolidated financial statements have been prepared using International Financial Reporting Standards ("IFRS") on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company's ability to continue as a going concern is dependent upon the ability of the Company to obtain financing and generate positive cash flows from its operations. As at November 30, 2018, the Company has a working capital deficit of \$6,344,747 and an accumulated deficit of \$31,334,169. The Company's loss for the six-month period ended November 30, 2018 is \$1,051,008.

Management of the Company does not expect that cash flows for the Company's operations will be sufficient to cover its operating requirements, financial commitments and business development priorities during the next twelve months. The Company will need to obtain further financing in the form of debt, equity or a combination thereof for the next twelve months to fund operations. There can be no assurance that additional funding will be available to the Company, or, if available, that this funding will be on acceptable terms. If adequate funds are not available, the Company may be required to delay or reduce the scope of its operations. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statement of financial position classification that would be necessary were the going concern assumption deemed to be inappropriate. These adjustments could be material.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

2. BASIS OF PRESENTATION

a) Statement of compliance to International Financial Reporting Standards

The condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") applicable to the preparation of condensed consolidated interim financial statements, including IAS 34, Interim Financial Reporting and using the same accounting policies and methods of computation as the Company's most recent annual consolidated financial statements. The condensed consolidated financial statements do not include all the information required for full annual financial statements. These condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended May 31, 2018.

The accounting policies followed by the Company are as set out in the audited financial statements for the year ended May 31, 2018 and have been consistently followed in the preparation of these condensed consolidated financial statements.

The consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments classified as fair value through profit and loss, and available for sale, which are stated at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The comparative figures presented in these consolidated financial statements are in accordance with IFRS.

These condensed consolidated financial statements were reviewed and approved and authorized for issue by the Board of Directors of the Company on January 29, 2019.

b) Significant accounting judgements and estimates

The preparation of the consolidated financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements. Actual results could differ from these estimates.

Critical Judgements

The preparation of these consolidated financial statements requires management to make judgements regarding the going concern of the Company, as previously discussed in Note 1, as well as determination of functional currency. The functional currency is the currency of the primary economic environment in which an entity operates and has been determined for each entity within the Company. The functional currency for the Company and its subsidiaries has been determined to be the U.S. dollar.

Key Sources of Estimation Uncertainty

Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity of IFRS requires management to make estimates that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be material. Significant estimates made by management affecting the consolidated financial statements include:

Notes to condensed consolidated interim financial statements November 30, 2018

(Unaudited - Expressed in U.S. Dollars)

2. BASIS OF PRESENTATION (cont'd...)

b) Significant accounting judgements and estimates (cont'd...)

Key Sources of Estimation Uncertainty (cont'd...)

i) Share-based Payments

Estimating the fair value for granted stock options and compensatory warrants requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate model including the expected life of the option or warrant, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

ii) Useful lives of property and equipment and intangible assets

Estimates of the useful lives of property and equipment and intangible assets are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factor and circumstances.

iii) Recovery of deferred tax assets

Judgment is required in determining whether deferred tax assets are recognized on the statement of financial position. Deferred tax assets, including those arising from un-utilized tax losses require management to assess the likelihood that the Company will generate taxable earnings in future years, in order to utilize recognized deferred tax assets. Estimates of future taxable income are based on forecast cash flows from operations and the application of existing tax laws in each jurisdiction. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted. Additionally, future changes in tax laws in the jurisdictions in which the Company operates could limit the ability of the Company to obtain tax deductions in future years.

iv) Carrying values of tangible and intangible assets

The Company assesses the carrying value of its tangible and intangible assets annually or more frequently if warranted by a change in circumstances. If it is determined that carrying values of assets cannot be recovered, the unrecoverable amounts are charged against current earnings. Recoverability is dependent upon assumption and judgements regarding market conditions, costs of operations and sustaining capital requirements. Other assumptions used in the calculation of recoverable amounts are discount rates, and future cash flows. A material change in the assumptions may significantly impact the potential impairment of these assets.

Notes to condensed consolidated interim financial statements November $30,\,2018$

(Unaudited - Expressed in U.S. Dollars)

2. BASIS OF PRESENTATION (cont'd...)

b) Significant accounting judgements and estimates (cont'd...)

Key Sources of Estimation Uncertainty (cont'd...)

v) Discount rates used in convertible debentures

The Company calculates the liability portion of convertible debentures by calculating the present value of the loan and related interest, using a discount rate equal to the market rate that would be given for similar debt, without a conversion feature. Management determines this rate by assessing what rate the Company could borrow funds at from an unrelated party.

v) Contingencies

By their nature, contingencies will only be resolved when one or more future events occur or fail to occur. The assessment of contingencies inherently involves the exercise of significant judgment and estimates of the outcome of future events.

c) Determination of functional currency

The functional currency is the currency of the primary economic environment in which the entity operates. Management has determined that the functional currency for the Company, and each of its subsidiaries is the U.S. dollars.

d) Basis of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries. Inter-company balances and transactions, and any unrealized income and expenses arising from inter-company transactions, are eliminated in preparing the consolidated financial statements.

Details of the Company's subsidiaries are as follows:

Name	Place of incorporation	Interest %	Principal activity
Certive Solutions Inc. (the	British Columbia,	100%	Management solutions
parent company)	Canada		
Certive Health Inc.	Arizona, United States	100%	Management solutions
(formerly Certive			
Technologies Arizona Inc.)			
Omega Technology	Florida, United States	100%	Healthcare revenue cycle
Solutions Inc. ("Omega")			management solutions
Knowledge Capital	Arizona, United States	100%	Performance management
Alliance, Inc. ("KCA")			solutions for public health
			agencies
Advantive Information	British Columbia,	100%	Dormant
Systems Inc.	Canada		

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

3. NEW AND FUTURE ACCOUNTING PRONOUNCEMENTS

Several new standards, amendments to standards and interpretations are not yet effective as at the date of issuing these statements and have not been applied in preparing these financial statements. The Company has not early adopted any of these standards and is currently evaluating the impact, if any, that these standards might have on its consolidated financial statements.

New Standards Adopted:

Amendments to $IFRS\ 2-Share-based\ payments$ - This amendment clarifies the measurement basis for cash-settled, share-based payments and the accounting for modifications that change an award from cash-settled to equity-settled.

IFRS 9 - Financial Instruments, addresses classification, measurement and recognition of financial assets and financial liabilities. This new standard is a partial replacement of IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 introduces new requirements for the classification and measurement of financial assets, additional changes relating to financial liabilities, a new general hedge accounting standard which will align hedge accounting more closely with risk management. The new standard also requires a single impairment method to be used, replacing multiple impairment methods in IAS 39.

IFRS 15 - Revenue from Contracts and Customers ("IFRS 15") replaced IAS 18, Revenue, IAS 11, Construction Contracts, and related interpretations on revenue. IFRS 15 sets out the requirements for recognizing revenue that apply to all contracts with customers, except for contracts that are within the scope of the Standards on leases, insurance contracts and financial instruments. IFRS 15 uses a control-based approach to recognize revenue which is a change from the risk and reward approach under the current standard.

IFRIC 22 - Foreign currency transactions and advance consideration - This IFRIC addresses foreign currency transactions or parts of transactions where there is consideration that is denominated or priced in a foreign currency.

Future Accounting Standards:

IFRS 16 - Leases, effective for annual periods beginning on or after 1 January 2019. The scope of IFRS 16 includes leases of all assets, with certain exceptions. A lease is defined as a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration. IFRS 16 requires lessees to account for all leases under a single on-balance sheet model in a similar way to finance leases under IAS 17. The standard includes two recognition exemptions for lessees — leases of 'low-value' assets (e.g. personal computers) and short-term leases (i.e. leases with a lease term of 12 months or less). At the commencement date of a lease, a lessee will recognize a liability to make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e. the right-of-use asset). Lessees will be required to separately recognize the interest expense on the lease liability and the depreciation expense on the right-of-use asset. Lessees will be required to remeasure the lease liability upon the occurrence of certain events (e.g. a change in the lease term, a change in future lease payments resulting from a change in an index or rate used to determine those payments). The lessee will generally recognize the amount of the remeasurement of the lease liability as an adjustment to the right-of-use asset. Lessor accounting is substantially unchanged from today's accounting under IAS 17. Lessors will continue to classify all leases using the same classification principle as in IAS 17 and distinguish between two types of leases: operating and finance leases.

Notes to condensed consolidated interim financial statements November 30, 2018

(Unaudited - Expressed in U.S. Dollars)

4. MARKETABLE SECURITIES

	Marketable Securities
Fair Value at May 31, 2018	\$ 7,474
Unrealized Gain	17,114
Monetary Exchange Rate	(530)
Fair Value at November 30, 2018	\$ 24,058

5. RECEIVABLES

	November 30, 2018	May 31, 2018
GST input tax credits	\$ 7,129	\$ 6,797
Trade receivables	185,421	69,834
Work in progress	269,333	269,333
	\$ 461,883	\$ 345,964

The average credit period on rendering of services is between 30 to 45 days. No interest is charged on outstanding trade receivables.

6. CUSTOMER LISTS

	Knowledge Capital Alliance Inc.			Omega Technology Solutions Inc.	Total		
Balance, May 31, 2017	\$	515,855	\$	480,000	\$ 995,855		
Impairment		_		(480,000)	(480,000)		
Balance, May 31 and November 30, 2018	\$	515,855	\$	-	\$ 515,855		

The Company acquired these customer lists as part of their acquisitions of KCA and Omega.

The Company considers KCA, and Omega to be separate cash generating units (CGU's). The Company assessed each of these CGUs for impairment as at November 30, 2018 and May 31, 2018 and has determined that KCA was not impaired as at November 30, 2018, and May 31, 2018. The Company determined that Omega was impaired as at May 31, 2018 and determined that its recoverable amount was \$Nil.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

7. SOFTWARE DEVELOPMENT

	Software Development
Cost:	
Balance at May 31, 2017	\$ 548,719
Additions	24,597
Balance at May 31 and November 30, 2018	\$ 573,316
Accumulated Amortization:	
Balance at May 31, 2017	\$ 114,969
Amortization	85,414
Balance at May 31, 2018	200,383
Amortization	39,139
Balance at November 30, 2018	\$ 239,522
Net Book Value:	
At May 31, 2018	\$ 372,933
At November 30, 2018	\$ 333,794

8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	November 30, 2018	May 31, 2018
Accounts payable (Note 14)	\$ 1,724,119	\$ 1,711,654
Accrued Liabilities	757,528	638,231
Payroll Liabilities (Note 17)	379,117	323,296
	\$ 2,860,764	\$ 2,673,181

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

9. NOTES PAYABLE

During the year ended May 31, 2018, the Company and the former owner of Omega Technologies Solution, LLC ("Omega") negotiated a further amount to be paid in connection with the acquisition of Omega. The Company has agreed to make a \$500,000 payment, which will also be used as settlement for any amounts owed between the Company and the former owner of Omega as follows:

- \$250,000 due on or before October 31, 2018
- Payment of an additional \$250,000 with the following terms:
 - o Quarterly payments equal to 25% of net income from the Omega division; and if the total amount of \$250,000 is not paid by February 28, 2020, the remaining balance will be due on that date; and no interest is to accrue during the pay-out period.

10. CONVERTIBLE DEBT

During the six-months ended November 30, 2018, the Company issued the following convertible notes:

- Convertible promissory note of \$60,000 on June 1, 2018, from a current officer and director of the Company (Note 14), maturing on May 1, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$3,825 was recorded as the equity component of the loan, and \$56,175 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on June 6, 2018 maturing on June 6, 2020. The note bears simple interest at 10% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price of \$0.03 per share, at the option of the lender. Of the total amount of the convertible note, \$4,893 was recorded as the equity component of the loan, and \$45,107 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$15,000 on June 19, 2018, from a current officer and director of the Company (Note 14), maturing on May 19, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$966 was recorded as the equity component of the loan, and \$14,033 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$10,000 on June 27, 2018, from a current officer and director of the Company (Note 14), maturing on May 27, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$644 was recorded as the equity component of the loan, and \$9,356 was recorded as a liability, using an effective interest rate of 15%.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

- Convertible promissory note of \$50,000 on July 11, 2018 maturing on July 11, 2019. The note bears simple interest at 18% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the lower of \$0.06 per share or the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$653 was recorded as the equity component of the loan, and \$49,347 was recorded as a liability, using an effective interest rate of 18%.
- Convertible promissory note of \$50,000 on July 11, 2018 maturing on July 11, 2019. The note bears simple interest at 15% per annum. Accrued interest to date shall be payable on September 30, 2018. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price of \$0.03 per share, at the option of the lender. Of the total amount of the convertible note, \$463 was recorded as the equity component of the loan, and \$49,537 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on July 16, 2018, from a current member of the Company's advisory council (Note 14), maturing on July 16, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$463 was recorded as the equity component of the loan, and \$49,537 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on August 16, 2018, from a current officer and director of the Company (Note 14), maturing on July 16, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$3,222 was recorded as the equity component of the loan, and \$46,778 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$10,000 on August 29, 2018, from a current officer and director of the Company (Note 14), maturing on July 29, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$644 was recorded as the equity component of the loan, and \$9,356 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on August 30, 2018, from a current officer and director of the Company (Note 14), maturing on July 30, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$3,222 was recorded as the equity component of the loan, and \$46,778 was recorded as a liability, using an effective interest rate of 15%.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

10. CONVERTIBLE DEBT (cont'd...)

- Convertible promissory note of \$25,000 on September 7, 2018, maturing on August 30, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$1,449 was recorded as the equity component of the loan, and \$23,551 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$100,000 on October 10, 2018, from a current member of the Company's advisory council (Note 14), maturing on February 26, 2020. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$9,572 was recorded as the equity component of the loan, and \$90,9428 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on October 11, 2018, from a current member of the Company's advisory council (Note 14), maturing on February 26, 2020. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$4,786 was recorded as the equity component of the loan, and \$45,214 was recorded as a liability, using an effective interest rate of 15%.

During the year ended May 31, 2018, the Company issued the following convertible notes:

• The Company converted an advance of \$157,640 (CDN\$200,000), made on June 15, 2017 into a convertible promissory note on February 28, 2018, maturing on February 26, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into 3,333,334 common shares of the Company. Of the total amount of the convertible note, \$17,240 was recorded as the equity component of the loan, and \$140,400 was recorded as a liability, using an effective interest rate of 15%. In addition, the Company issued 3,333,400 warrants exercisable into common shares of the Company at a price of CDN\$0.06 expiring on February 26, 2020. These warrants were valued at \$38,721 using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of these transaction costs, \$4,235 was recorded as an equity component of the transaction costs, with the remainder amortized over the term of the loan. In addition, 666,700 shares valued at \$24,691 were issued to the lender of this note and recorded as transaction costs. Of these transaction costs, \$2,700 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

- The Company converted an advance of \$157,640 (CDN\$200,000), made on June 15, 2017 into a convertible promissory note on February 28, 2018, maturing on February 28, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into 3,333,334 common shares of the Company. Of the total amount of the convertible note, \$17,240 was recorded as the equity component of the loan, and \$140,400 was recorded as a liability, using an effective interest rate of 15%. In addition, the Company issued 3,333,334 warrants exercisable into common shares of the Company at a price of CDN\$0.06 expiring on February 26, 2020. These warrants were valued at \$38,721 using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of these transaction costs, \$4,235 was recorded as an equity component of the transaction costs, with the remainder amortized over the term of the loan in addition, 1,000,000 shares valued at \$30,628 were issued to the lender of this note and recorded as transaction costs. Of these transaction costs, \$3,350 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.
- The Company converted an advance of \$45,000 made in July 2017 into a convertible promissory note on February 28, 2018 maturing on February 26, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price of \$0.03 per share at the option of the lender. Of the total amount of the convertible note, \$4,403 was recorded as the equity component of the loan, and \$40,597 was recorded as a liability. The Company issued 1,500,000 warrants exercisable into common shares of the Company at a price of \$0.06 expiring on February 26, 2020 valued at \$16,872 for this note. These warrants were valued using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of the total value of the transaction costs, \$1,651 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.
- The Company converted advances of \$82,500 made on August 15, 2017 into convertible promissory notes on February 28, 2018 maturing on February 26, 2020. The notes bear interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all the notes. The notes are convertible into common shares of the Company at a price of \$0.06 per share at the option of the lender. Of the total amount of the convertible notes, \$8,073 was recorded as the equity component of the loans, and \$74,427 was recorded as a liability, using an effective interest rate of 15%. The Company issued 750,000 warrants, exercisable into common shares of the Company at a price of \$0.06 expiring on February 26, 2020, valued at \$8,436 for these notes. These warrants were valued using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of the total value of the transaction costs, \$826 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

- The Company converted an advance of \$60,000 made on August 15, 2017 into a convertible promissory note on February 28, 2018 maturing on February 28, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price of \$0.03 per share at the option of the lender. Of the total amount of the convertible note, \$5,871 was recorded as the equity component of the loan, and \$54,129 was recorded as a liability. The Company issued 2,000,000 warrants, exercisable into common shares of the Company at a price of \$0.06 expiring on February 26, 2020, valued at \$22,496 for this note. These warrants were valued using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of the total value of the transaction costs, \$2,201 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.
- The Company converted an advance of \$50,000 made on October 4, 2017, from the current officer and director of the Company (Note 14), into a convertible promissory note on February 26, 2018 maturing on February 26, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price of \$0.05 per share at the option of the lender. Of the total amount of the convertible note, \$4,893 was recorded as the equity component of the loan, and \$45,107 was recorded as a liability. The Company issued 1,000,000 warrants, exercisable into common shares of the Company at a price of \$0.05 expiring on February 26, 2020, valued at \$11,636 for this note. These warrants were valued using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of the total value of the transaction costs, \$1,139 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.
- The Company converted an advance of \$295.575 (CDN\$375,000), made on October 16, 2017 into a convertible promissory note on February 28, 2018, maturing on February 26, 2020. This loan was issued at a discount, with the Company receiving \$279,335 (CAD\$350,000). The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into 9,375,000 common shares of the Company. Of the total amount of the convertible note, \$28,923 was recorded as the equity component of the loan, and \$266,652 was recorded as a liability, using an effective interest rate of 15%. The Company is to issue 3,125,000 shares valued at \$98,525 to the lender of this note and have been recorded as transaction costs. Of these transaction costs, \$9,641 was recorded as the equity component, with the remained to be amortized over the term of the note. In addition, the Company issued 9,375,000 warrants, exercisable into common shares of the Company at a price of CDN\$0.04 expiring on February 26, 2020, valued at \$116,354 for this note. These warrants were valued using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of the value of these transaction costs, \$12,167 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

- The Company converted an advance of \$50,000 made on November 2, 2017 into a convertible promissory note on February 28, 2018 maturing on February 26, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price of \$0.05 per share at the option of the lender. Of the total amount of the convertible note, \$4,893 was recorded as the equity component of the loan, and \$45,107 was recorded as a liability. The Company issued 1,000,000 warrants, exercisable into common shares of the Company at a price of \$0.05 expiring on February 26, 2020, valued at \$11,636 for this note. These warrants were valued using the Black Scholes option pricing model with an expected volatility of 185.24%, discount rate of 1.78%, expected life of 2 years, and a dividend rate of 0%. Of the total value of the transaction costs, \$1,139 was recorded as a cost of the equity component of the convertible note. The remainder was recorded against the liability portion of the note and will be amortized over the term of the note.
- The Company converted an advance of \$90,000 made on November 24, 2017 into a convertible promissory note on November 24, 2017 maturing on November 24, 2019. The note bears interest at 10% per annum payable at maturity, calculated semi-annually up to and including the term of the note. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price of \$0.04 per share at the option of the lender. Of the total amount of the convertible note, \$8,806 was recorded as the equity component of the loan, and \$81,194 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on March 26, 2018 with a maturity date of March 26, 2020. The note bears interest at 10% per annum payable at maturity, calculated semi-annually. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price of \$0.03 per share at the option of the lender. Of the total amount of the convertible note, \$4,893 was recorded as the equity component of the loan, and \$45,107 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$100,000 on March 28, 2018, from a current officer and director of the Company (Note 14), maturing on February 28, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$5,854 was recorded as the equity component of the loan, and \$94,146 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$25,000 on March 29, 2018 maturing on March 1, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$1,445 was recorded as the equity component of the loan, and \$23,555 was recorded as a liability, using an effective interest rate of 15%.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

- Convertible promissory note of \$25,000 on March 29, 2018 maturing on February 28, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$1,604 was recorded as the equity component of the loan, and \$23,396 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$25,000 on March 30, 2018, from a current member of the Company's advisory council (Note 14), maturing on March 30, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$1,449 was recorded as the equity component of the loan, and \$23,551 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$50,000 on April 20, 2018 maturing on April 20, 2020. The note bears interest at 10% per annum, calculated semi-annually. The Company shall not be penalized for early repayment of any, or all of the note. The note is convertible into common shares of the Company at a price of \$0.03 per share at the option of the lender. Of the total amount of the convertible note, \$4,893 was recorded as the equity component of the loan, and \$45,107 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$25,000 on May 4, 2018, from a current director of the Company (Note 14), maturing on March 30, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$1,739 was recorded as the equity component of the loan, and \$23,261 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$7,500 on May 21, 2018, from a current director of the Company (Note 14), maturing on April 21, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$435 was recorded as the equity component of the loan, and \$7,065 was recorded as a liability, using an effective interest rate of 15%.
- Convertible promissory note of \$25,000 on May 31, 2018, from a current director of the Company (Note 14), maturing on April 30, 2019. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender. Of the total amount of the convertible note, \$1,464 was recorded as the equity component of the loan, and \$23,526 was recorded as a liability, using an effective interest rate of 15%.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

10. CONVERTIBLE DEBT (cont'd...)

During the year ended May 31, 2018, the Company modified terms for certain convertible notes issued during the year ended May 31, 2017:

- For the convertible notes of \$150,000 issued on May 1, 2017, the Company extend this maturity of this note to February 26, 2020 and issued 524,000 warrants valued at \$4,802.
- For the convertible note of \$100,000 issued on March 20, 2017, the Company extend this maturity of this note to February 26, 2020 and issued 350,000 warrants valued at \$3,201.

As at November 30, 2018 and May 31, 2018, the Company has the following convertible notes outstanding:

	No	vember 30, 2018	May 31, 2018
Convertible notes over due	\$	677,086	\$ 699,060
Convertible notes due within 12 months of year end date		1,482,232	1,028,194
Convertible notes due after 12 months from year end		1,321,270	1,211,801
Transaction costs and bond discounts		(256,134)	(411,913)
	\$	3,224,454	\$ 2,527,142

11. SHORT-TERM LOANS

The loans are made up of the following:

	November 30, 2018	May 31, 2018
Loans from related parties (Note 14)	\$ 250,792	\$ 31,326
Loans from other entities	8,000	8,000
	\$ 258,792	\$ 139,326

All loans payable does not have any terms of repayment.

Notes to condensed consolidated interim financial statements November $30,\,2018$

(Unaudited - Expressed in U.S. Dollars)

12. SHARE CAPITAL

a) Common and preferred stock

Authorized - Unlimited common and preferred shares without par value.

During the six-months ended November 30, 2018, the Company had the following share capital transactions:

- The Company issued the 3,125,000 shares that were to be issued, valued \$98,525 as transaction costs on convertible notes.
- The Company issued 374,326 shares valued at \$7,772 for consulting fees.
- The Company issued 1,300,000 shares valued at \$240,000 for acquisition of Omega, that were previously recorded as other equity reserves.
- The Company reached a settlement agreement with a vendor, whereby the Company will issue 1,000,000 shares in settled of outstanding debt owing. As at November 30, 2018, these shares had not yet issued, and the debt is not considered cancelled until such issuance of these shares. As a result, this has not been recorded as at November 30, 2018.

During the six-months ended November 30, 2017, the Company had the following share transactions:

- The Company issued 1,666,700 shares valued at \$55,319 as transaction costs on convertible notes.
- The Company returned 2,240,000 shares valued at \$82,886 to treasury for Titan's discontinuation.

b) Share purchase warrants

The following table summarizes the continuity of share purchase warrants:

	Number of Warrants	Weighted Average Exercise Price
Outstanding, May 31, 2017	10,424,593	\$ 0.26
Issued	23,166,734	0.05
Exercised	(1,333,333)	0.35
Outstanding, May 31, 2018	32,257,994	\$ 0.10
Expired	(6,591,260)	0.30
Outstanding, November 30, 2018	25,666,734	\$ 0.05

As at November 30, 2018, the Company had the following share purchase warrants outstanding:

Outstanding	Exercise Price	Remaining Life (Years)	Expiry Date
2,500,000	CDN\$0.15	0.15	January 23, 2019 (subsequently expired)
6,666,734	CDN\$0.06	1.24	February 26, 2020
875,000	\$0.15	1.24	February 26, 2020
4,250,000	\$0.06	1.24	February 26, 2020
9,375,000	CAD\$0.04	1.24	February 26, 2020
2,000,000	\$0.05	1.24	February 26, 2020
25,666,734	\$0.05	1.13	

Notes to condensed consolidated interim financial statements November 30, 2018

(Unaudited - Expressed in U.S. Dollars)

12. SHARE CAPITAL (cont'd...)

c) Stock options

The Company's Stock Option Plan is a 20% rolling plan that allows a maximum 20% of the issued shares to be reserved for issuance under the plan. Options granted under the plan may not have a term exceeding 5 years and vesting provisions are at the discretion of the Board of Directors.

The following is a summary of stock option activities during the year ended May 31, 2018 and the six-months ended November 30, 2018:

	Number of Stock Options	Weighted Average Exercise Price
Outstanding, May 31, 2018, and May 31, 2017	11,102,493	\$0.19
Expired	(4,750,000)	CDN\$0.25
Outstanding November 30, 2019	6,352,493	\$0.20

At November 30, 2018, the following stock options were outstanding to directors, officers and employees:

			Remaining Life	}
Outstanding	Exercisable	Exercise Price	(Years)	Expiry Date
4,252,493	4,252,493	CDN\$0.25	2.09	December 31, 2020
2,100,000	2,100,000	\$0.22	2.79	September 13, 2021
6,352,493	6,352,493	\$0.20	2.32	

The Company recognizes compensation expense for all stock options granted using the fair value-based method of accounting. No options were issued during the six-months ended November 30, 2018 or 2017

d) Transactions costs reserve

The transactions costs reserve is used to record the costs directly attributable to the issue of common shares and share purchase options and is recognized as a deduction from equity, net of any tax effects.

e) Other equity instruments

This consists of \$600,000 for shares to be issued upon the conversion of the Omega note. During the period ended November 30, 2018, the Company issued 1,300,000 common shares valued at \$240,000, which were previously held to be issued in conjunction with the acquisition of Omega.

Notes to condensed consolidated interim financial statements November 30, 2018

(Unaudited - Expressed in U.S. Dollars)

13. DERIVATIVE LIABILTY

The derivative financial liability consists of the fair value of non-compensatory share purchase warrants and convertible notes that have an exercise price or a conversion price that differs from the functional currency of the Company. Details of the derivative liability as at November 30, 2018 and May 31, 2018 is as follows:

As at November 30, 2018:

Expiration Date	Exercise Number of securities biration Date price exercisable/convertible		Fair value as at November 30, 2018	
March 23, 2019	CDN\$0.15	2,666,667	\$	24,257
March 23, 2019	CDN\$0.15	4,666,667		20,049
January 23, 2019	CDN\$0.15	2,500,000		10,741
February 26, 2020	CDN\$0.06	3,333,334		74,811
February 26, 2020	CDN\$0.06	3,333,400		74,813
February 26, 2020	CDN\$0.04	9,375,000		223,123
		25,875,068	\$	427,794

These securities were valued using the Black Scholes option pricing model with a weighted average expected volatility of 255.40%, discount rate of 1.87%, expected life of 0.85 years, and a dividend rate of 0%.

As at May 31, 2018:

Expiration Date	Exercise price	Number of securities exercisable/convertible		Fair value as at May 31, 2018
November 30, 2018	CDN\$0.50	2,635,015	\$	20,409
November 30, 2018	CDN\$0.60	254,722		1,816
March 23, 2019	CDN\$0.15	2,666,667		38,729
March 23, 2019	CDN\$0.15	4,666,667		64,356
January 23, 2019	CDN\$0.15	2,500,000		34,477
November 21, 2018	CDN\$0.15	1,600,000		18,654
February 26, 2020	CDN\$0.06	3,333,334		63,081
February 26, 2020	CDN\$0.06	3,333,400		63,082
February 26, 2020	CDN\$0.04	9,375,000		184,566
		30,364,805	\$	489,170

These securities were valued using the Black Scholes option pricing model with a weighted average expected volatility of 266.05% discount rate of 1.87%, expected life of 1.22 years, and a dividend rate of 0%.

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

14. RELATED PARTY TRANSACTIONS

Balances and transactions between the Parent Company and its consolidated subsidiaries, which are related parties of the Parent, have been eliminated on consolidation and are not disclosed in this note.

The Company's related parties consist of its Directors, Key Management Personals ("KMPs") and companies owned in whole or in part by KMPs and directors as follows:

Name	Position and nature of relationship
LiteLink Technologies Inc. (Formerly AXS Blockchain Solutions Inc	
formerly Canadian Data Preserve, Inc.) ("LiteLink")	Company with common former directors
Bridge Business Development	Company controlled by former director
	Company controlled by key management
MoeVela, LLC	personnel
	Company controlled by key management
SMA Group, LLC	personnel
	Company controlled by the corporate
Miller and Associates Environmental Consultants Inc.	secretary
	Company controlled by key management
Precision Health Systems	personnel
•	Director and officer, and former advisory
Tim Hyland	board member
	Director, officer, and former advisory board
Tom Marreel	member
Jeff Wareham	Director
Jack Saltich	Director
Scott Thomas	Director
Brian Cameron	Director and former officer
Mike Miller	Corporate secretary
Susan Miller	Spouse of the corporate secretary
Fredrick Erickson	Key management personnel
Ann Fierro	Key management personnel
Timothy Tolchin	Key management personnel
Van Potter	Former director and former officer
Michael Bartlett	Former director
John Shackleton	Former director
Edwin Holder	Former director
Mary Ann Miller	Former director
Thomas Hoehner	Former key management personnel
Todd Hisey	Former key management personnel
Jeff Benton	Advisory council member
Arthur Pelberg	Advisory council member
Bob Uxa	Advisory council member
Jack Chapman	Advisory council member
Steve Schramm	Advisory council member
Don Gilbert	Advisory council member

Notes to condensed consolidated interim financial statements November 30, 2018 (*Unaudited - Expressed in U.S. Dollars*)

14. RELATED PARTY TRANSACTIONS (cont'd...)

The amounts due to the related parties are as follows:

	Nature of relationship	November 30, 2018	May 31, 2018
	Directors, key management personnel, and		
Accounts payable (Note 8)	companies controlled by these parties,	\$ 666,361	\$ 716,072
Convertible loans – face value (Note 10)	Directors	\$ 402,500	\$ 207,500
Convertible loans – face value (Note 10)	Advisory council members	\$ 325,000	\$ 125,000
Note payable (Note 9)	Key management personnel	\$ 500,000	\$ 500,000
Short-term loans payable (Note 11)	Key management personnel	\$ 96,792	\$ 106,326
Short-term loans payable (Note 11)	Former director and former officer	\$ 24,000	\$ 25,000
Short-term loans payable (Note 11) (1)	Directors	\$ 130,000	\$ -
Total		\$ 2,144,653	\$ 1,679,898

⁽¹⁾ These short-term loans payable are due on demand and have an interest rate of 12% per annum.

The Company incurred the following fees and expenses in the normal course of operations in connection with companies owned by key management and directors. Expenses have been measured at the exchange amount which is determined based on actual cost. There is no other remuneration of directors or other members of key management personnel during the six-months ended November 30, 2018 and 2017 other than as follows:

	November 30, 2018	November 30, 2017
Management fees	\$ 54,000	\$ 288,000
Salaries to key management personnel, included in operating costs and expenses	183,822	173,592
Consulting fees	51,572	-
Directors' fees	10,000	122,200
Advisory board fees to a former advisory council member, and current director.	12,000	45,000
Total	\$ 311,394	\$ 628,792

15. MANAGEMENT OF CAPITAL

The Company manages its common shares, stock options and share purchase warrants as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its assets and to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk. The Company is not subject to any externally imposed capital requirements.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, issue debt or acquire or dispose of assets.

In order to facilitate the management of its capital requirements, the Company prepares expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions.

In order to maximize its efforts, the Company does not pay out dividends. The Company's investment policy is to keep its cash treasury invested in demand certificates of deposit with major financial institutions. There have been no changes to the Company's approach to capital management during the six-months ended November 30, 2018.

Notes to condensed consolidated interim financial statements November 30, 2018

(Unaudited - Expressed in U.S. Dollars)

16. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial risk management

The board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's financial instruments consist of cash, receivables, marketable securities, accounts payable, convertible debt, short-term loans, and note payable.

The fair values of cash and marketable securities are measured on the statement of financial position using level 1 of the fair value hierarchy. The fair value of convertible debt is measured on the statement of financial position using level 3 of the fair value hierarchy. The fair values of receivables, accounts payable, short-term loans and notes payable, approximate their book values because of the short-term nature of these instruments. The long-term portion of the Company's note payable approximates its fair value as it non-interesting bearing.

Financial instrument risk exposure

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board approves and monitors the risk management processes.

a) Credit risk

Credit risk is the risk of financial loss to the Company if counterparty to a financial instrument fails to meet its payment obligations. The Company has no material counterparties to its financial instruments with the exception of the financial institutions which hold its cash. The Company manages this credit risk by ensuring that these financial assets are placed with a major financial institution with strong investment grade ratings by a primary ratings agency. The Company's receivables consist primarily of harmonized sales tax due from the Canada Revenue Agency. The Company does not believe it has a material exposure to credit risk.

b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure as described in Note 15. There is a risk that the Company may not be able to meet its financial obligation when they are due. All of the Company's financial liabilities have contractual maturities of 30 days or are due on demand and are subject to normal trade terms.

c) Market risk

Market risk is the risk of loss that may arise from changes in market factors such as foreign exchange rates, interest rates, and commodity and equity prices:

(i) Foreign exchange risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the foreign currency exchange rates. The Company's functional currency is the United States dollar as the Company's main center of operations is the United States. As at November 30, 2018, the Company has approximately CDN\$3,069,000 of financial liabilities denominated in Canadian dollars. A 10% change in exchange rate would result on a change to loss and comprehensive loss of approximately \$231,000.

Notes to condensed consolidated interim financial statements November 30, 2018

(Unaudited - Expressed in U.S. Dollars)

16. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (cont'd...)

(ii) Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize a loss as a result of interest rate risk on its notes payable is minimal, as these have a short-term to maturity, and a fixed interest rate.

(iii) Price risk

The Company is not exposed to significant price risk as it does not hold significant investments in publicly traded securities. The Company's price risk is limited to the value of its marketable securities.

17. CONTINGENT LIABILTY

During the year ended May 31, 2018, the Company received correspondence from the IRS regarding the Company's withholding of payroll taxes from its employees that have not been remitted to the IRS. As at November 30, 2018, the Company has fully recorded this obligation of approximately \$380,000 in its payroll liabilities (Note 8).

18. SUBSEQUENT EVENTS

- Subsequent to November 30, 2018, the Company entered into a convertible promissory note of \$100,000 on December 21, 2018, from a current advisory council member of the Company maturing on February 26, 2020. The note bears simple interest at 8% per annum. The Company shall not be penalized for early repayment of any, or all the note. The note is convertible into common shares of the Company at a price the higher of \$0.06 per share or a 25% discount to the price per share on the date of conversion, at the option of the lender.
- Subsequent to November 30, 2018, the Company assisted a shareholder with the cancellation of 328,496 shares which are being returned to Treasury.
- Subsequent to November 30, 2018, a convertible note for CDN\$700,000 became delinquent and the Company is in discussions with the lender to extend the term.
- Subsequent to November 30, 2018, 2,500,000 share warrants, exercisable at CDN\$0.15 expired unexercised.
- Subsequent to November 30, 2018, the Board of Directors granted 4,400,000 stock options to the Company's executive management and certain members of Board of Directors.